Entities

Justine Canavy serves as Financial Controller at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to July 2026. Earlier professional experience described by the firm includes Mazars.

Léo Chalmel serves as Associate at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to March 2024. The biography lists education or professional training at EM Lyon. Earlier professional experience described by the firm includes Natixis, Ardian.

Maxence Bédué serves as Associate at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to September 2024. The biography lists education or professional training at ESSEC. Earlier professional experience described by the firm includes InfraRed Capital Partners, BNP Paribas.

Romain Campi serves as Director at Omnes Capital. The current directory assigns this position to Digital Infrastructure. The published career history dates joining the firm or team to April 2023. The biography lists education or professional training at ESCP. Earlier professional experience described by the firm includes EY.

Timothée Chailley serves as Analyst at Omnes Capital. The current directory assigns this position to Digital Infrastructure. The biography lists education or professional training at HEC, EDHEC.

Alberto Priori, MD, PhD, is a Newronika co-founder and Chairman of its Scientific Advisory Board. The company identifies him as a University of Milan neurologist; its initial financing release describes his pioneering research on central-nervous-system stimulation as a foundation of Newronika’s technology. He is an author in the company’s current peer-reviewed clinical publication list on adaptive DBS for Parkinson’s disease.

Archer Kilpatrick serves as Director at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to May 2025. Previous renewable-energy work spans project finance, solar development and Actis investments across Africa and Eastern Europe.

Camille Leonard serves as Director at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to June 2019. Earlier professional experience described by the firm includes KPMG.

Camille Zimmermann serves as Director at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to 2023. The biography lists education or professional training at ESCP.

Hassan Al Azadi serves as Principal at Omnes Capital. The current directory assigns this position to Portfolio Management. The published career history dates joining the firm or team to September 2024. Earlier portfolio work includes Tikehau and Access Capital Partners, supported by financial-markets training at Skema.

Jayden Aryee serves as Communications Associate at Omnes Capital. The current directory assigns this position to Communications. The published career history dates joining the firm or team to January 2024. Prior internships include LVMH transformation and Hilti recruitment; his BBA is from St.Gallen.

Rihab Aqarrout serves as Analyst at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to July 2026. Earlier professional experience described by the firm includes Crédit Agricole.

Thomas Abulius serves as In-house Counsel at Omnes Capital. The current directory assigns this position to Legal Operations. The published career history dates joining the firm or team to February 2024. The biography lists education or professional training at ESCP.

Yasmine Lazrak serves as Director at Omnes Capital. The current directory assigns this position to Co-Investment. The published career history dates joining the firm or team to December 2023. Earlier Bain work in Toronto covered private-equity diligence and performance improvement; she studied commerce at McGill.

Benjamin Stremsdoerfer serves as Partner at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to March 2018. The biography lists education or professional training at Ecole Polytechnique, Imperial College. Earlier professional experience described by the firm includes L.E.K.

Caroline Yametti serves as Partner at Omnes Capital. The current directory assigns this position to Digital Infrastructure. The published career history dates joining the firm or team to 2017. The biography lists education or professional training at HEC. Earlier professional experience described by the firm includes InfraRed Capital Partners, HSBC.

Eduardo Bozo serves as Head of Portfolio Management at Omnes Capital. The current directory assigns this position to Portfolio Management. The published career history dates joining the firm or team to January 2024. Earlier Actis experience spans20 years, including Latin America and London and energy/infrastructure chief operating officer responsibilities.

Estelle Eonnet serves as Director - Head of Communications at Omnes Capital. The current directory assigns this position to Communications. The published career history dates joining the firm or team to 2023. The biography lists education or professional training at Sciences Po.

Isaure d’Autichamp serves as Director - Investor Relations at Omnes Capital. The current directory assigns this position to Investor Relations. The published career history dates joining the firm or team to May 2025. The biography lists education or professional training at Dauphine.

Maia Falkå serves as Director at Omnes Capital. The current directory assigns this position to Venture Capital & Growth. The published career history dates joining the firm or team to October 2022. Earlier roles include LeadX Capital Partners and Simon-Kucher; education spans Exeter and ESB Business School.

Mehdi Abdallah serves as Head of Funds Financial Control at Omnes Capital. The current directory assigns this position to Finance Operations. The published career history dates joining the firm or team to November 2018. The biography lists education or professional training at EM Lyon. Earlier professional experience described by the firm includes Mazars.

Yannic Trüb serves as Partner at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to May 2014. The biography lists education or professional training at Sciences Po, University of Zurich.

Fabien Collangettes serves as Partner at Omnes Capital. The current directory assigns this position to Venture Capital & Growth. The published career history dates joining the firm or team to January 2017. The biography lists education or professional training at Imperial College.

François-Xavier Dedde serves as Partner at Omnes Capital. The current directory assigns this position to Venture Capital & Growth. The biography lists education or professional training at EM Lyon. Earlier professional experience described by the firm includes Crédit Lyonnais, Crédit Agricole.

Grégoire Samain serves as Partner, Head of Project Management and Client Servicing - Investor Relations at Omnes Capital. The current directory assigns this position to Investor Relations. The published career history dates joining the firm or team to 2014. The biography lists education or professional training at Université Paris.

Jean-Baptiste Delattre serves as Partner at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure. The published career history dates joining the firm or team to January 2018. Earlier ArcelorMittal work included maintenance leadership and responsibility for global energy supplies and strategic energy partnerships.

Miria Späth-Werder serves as Partner, Head of Sales - Investor Relations at Omnes Capital. The current directory assigns this position to Investor Relations. The published career history dates joining the firm or team to 2016. Earlier professional experience described by the firm includes PwC, Akina.

Morgane Honikman serves as Partner at Omnes Capital. The current directory assigns this position to Digital Infrastructure. The published career history dates joining the firm or team to October 2018. The biography lists education or professional training at ESSEC.

Renaud Poulard serves as Partner at Omnes Capital. The current directory assigns this position to Venture Capital & Growth. The biography lists education or professional training at INSEAD. His earlier Sagem research covered telecoms and defence, followed by venture investing at Seventures; the biography dates his Omnes move to2005.

Simon Hardi serves as Partner - Head of Co-Investment at Omnes Capital. The current directory assigns this position to Co-Investment. The published career history dates joining the firm or team to October 2019. Earlier professional experience described by the firm includes L.E.K.

Gonzague de Tremiolles serves as Partner - Head of Digital Infrastructure at Omnes Capital. The current directory assigns this position to Digital Infrastructure, Executive Committee. The published career history dates joining the firm or team to 2016. The biography lists education or professional training at Sciences Po, Université Paris, Dauphine.

Lina Zovic serves as Partner - CFO at Omnes Capital. The current directory assigns this position to Executive Committee, Finance Operations, ESG & Sustainability. The published career history dates joining the firm or team to September 2024. The biography lists education or professional training at Audencia. Earlier professional experience described by the firm includes KPMG.

Marc-Philippe Botte serves as Managing Partner at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure, Executive Committee, Investor Relations. His earlier career spans teaching at the Free University of Brussels and renewable-energy M&A at Fortis Bank.

Michael Pollan serves as Managing Partner at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure, Executive Committee, ESG & Sustainability. The published career history dates joining the firm or team to 2013. Earlier professional experience described by the firm includes Natixis.

Michel de Lempdes serves as Managing Partner at Omnes Capital. The current directory assigns this position to Venture Capital & Growth, Executive Committee, Human Resources. The biography lists education or professional training at NEOMA. Earlier professional experience described by the firm includes Crédit Lyonnais, Crédit Agricole.

Philippe Trolez serves as Partner - Corporate Secretary at Omnes Capital. The current directory assigns this position to Executive Committee, Legal Operations. The published career history dates joining the firm or team to 2001. The biography lists education or professional training at HEC.

Roshini Jain is publicly named by Newronika as Clinical Strategy. The current affiliation is verified by the company’s own directory as reviewed October8,2026.

Serge Rakovitch serves as Partner - COO at Omnes Capital. The current directory assigns this position to Executive Committee, Finance Operations. The published career history dates joining the firm or team to June 2017. The biography lists education or professional training at HEC. Earlier professional experience described by the firm includes Crédit Lyonnais, Deloitte.

Serge Savasta serves as Chief Executive Officer & Chief Investment Officer at Omnes Capital. The current directory assigns this position to Energy Transition Infrastructure, Digital Infrastructure, Co-Investment, Executive Committee. The published career history dates joining the firm or team to 2006. The biography lists education or professional training at HEC. Earlier professional experience described by the firm includes Crédit Lyonnais.

Claudia Preziosi is publicly named by Newronika as Business Strategy. The current affiliation is verified by the company’s own directory as reviewed October8,2026.

Blayne Fleck is publicly named by Newronika as Business Strategy. The current affiliation is verified by the company’s own directory as reviewed October8,2026.

Alberto Grando is publicly named by Indaco Venture Partners SGR in its governance directory as Board Member. This is a manager-governance affiliation; additional career history and the term of appointment are not established by this source.

Antonio Mele is publicly named by Indaco Venture Partners SGR in its governance directory as Statutory Auditor. This is a manager-governance affiliation; additional career history and the term of appointment are not established by this source.

Carlo Viola is publicly named by Indaco Venture Partners SGR in its governance directory as Board Member. This is a manager-governance affiliation; additional career history and the term of appointment are not established by this source.

Federica Mantini is publicly named by Indaco Venture Partners SGR in its governance directory as Chairman of the Board of Statutory Auditors. This is a manager-governance affiliation; additional career history and the term of appointment are not established by this source.

Giuseppe Galeano is publicly named by Indaco Venture Partners SGR in its governance directory as Statutory Auditor. This is a manager-governance affiliation; additional career history and the term of appointment are not established by this source.

Luca Pagetti is publicly named by Indaco Venture Partners SGR in its governance directory as Board Member. This is a manager-governance affiliation; additional career history and the term of appointment are not established by this source.

Marco Seracini is publicly named by Indaco Venture Partners SGR in its governance directory as Board Member. This is a manager-governance affiliation; additional career history and the term of appointment are not established by this source.

Salvatore Bragantini is publicly named by Indaco Venture Partners SGR in its governance directory as Chairman of the Board. This is a manager-governance affiliation; additional career history and the term of appointment are not established by this source.

Named in Indaco's April2018 launch announcement as one of five key managers who collectively owned51% of the manager. Her disclosed capacity was Investment Director; current affiliation is not established by that historical release.

Carlo is an Indaco investment manager specialising in healthcare and life sciences. Previously worked atEsaote in diagnostic devices and led technology-transfer projects atIIT RehabTechnologies from2012 to2016. Co-founded Movendo Technology in2017 and served as COO and Product Development Director, including clinical/regulatory development. Holds a Genoa physics degree.

Costanza Conti is publicly named by Newronika as Clinical Affairs Manager. The current affiliation is verified by the company’s own directory as reviewed October8,2026.

Navisalma is a European venture platform that combines investment capital, engineering, product and brand design, and operational business building to scale frontier technology companies. It works alongside founders, existing owners and investors to turn technical breakthroughs into products, accelerate adoption and operations, and build companies capable of industrial scale. Its model connects venture capital’s focus on frontier technology with private equity’s execution and value creation discipline. The founders draw on their experience building autonomous electric-freight company Einride, while its first explicitly backed company, Abundry, applies technology and decision intelligence to energy infrastructure. The platform includes Navisalma Ventures and Navisalma Design; those published divisions are distinct from any independently verified legal fund or investment vehicle.

co-founded Einride in2016 and built its global identity. Current own directory names CEO Navisalma Design; own launch quote identifies Founding Partner.

Marcello Casali is publicly named by Newronika as Manager - Quality, Regulatory, & Manufacturing. The current affiliation is verified by the company’s own directory as reviewed October8,2026.

engineer, founded Einride in2016, now Einride chairman and helps shape companies Navisalma builds.

engineer and former McKinsey Partner, co-founded Material Economics in2016, acquired by McKinsey in2021. Works closely with companies Navisalma builds.

Mattia Arlotti is publicly named by Newronika as VP - Engineering & New Product Development. The current affiliation is verified by the company’s own directory as reviewed October8,2026.

Ioannis U. Isaias is publicly named by Newronika as Chief Medical Officer. The current affiliation is verified by the company’s own directory as reviewed October8,2026. The visible team card misspells his surname Isais, while the same issuer’s structured Person data and listed peer-reviewed research identify Ioannis U. Isaias/IsaiasIU. The canonical identity follows those corroborating primary records.

Lorenzo Rossi, PhD, is Newronika’s co-founder, Chief Executive Officer and Chief Technology Officer. He is a bioengineer and repeat entrepreneur whose work with Alberto Priori underpins the company’s adaptive deep-brain-stimulation technology. He led the issuer’s 2016 and2019 financing announcements and the September2026 announcement of first ADVENT study implantation. The company’s current directory confirms the combined CEO/CTO role.

Keith Carlton is Newronika’s Executive Chairman, appointed effective immediately on September8,2025. The issuer describes executive leadership experience in medical devices and neuromodulation, including innovation, strategic growth and operational management. Its current directory retains him as Executive Chairman.

Newronika S.p.A. is an Italian neurotechnology and medical-device company developing adaptive deep brain stimulation for Parkinson’s disease and researching further neuromodulation applications. Founded in2009 as a spin-off of Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico and the University of Milan, its αDBS/AlphaDBS platform combines implanted neural sensing, a closed-loop stimulation algorithm, a clinician interface and patient remote. The latest commercial system integrates WebBioBank, its cloud platform for longitudinal neural data. The2025 financing announcement describes real-time neural data and machine-learning integration as a development aim, not proof of autonomous clinical decision-making or efficacy for every neurological indication. The current primary directory lists nine leadership/functional members and seven scientific advisers, including ExecutiveChairman KeithCarlton, Co-Founder/CEO/CTO LorenzoRossi and ChiefMedicalOfficer IoannisU.Isaias. The legal issuer is NewronikaS.p.A., VATIT06399770962/REAMI-1890329; headquarters ViaTorquatoTasso1,20093 ColognoMonzese(Milan), with legal address ForoBuonaparte57,20121 Milan. The separately identified NewronikaUSAInc location is a subsidiary and is not treated as another Italian parent headquarters or issuer. The company reports its latest integrated αDBS commercial release CE-marked in the European Economic Area in July2026; its September30,2026 announcement states the first ADVENT pivotal-study participant was implanted September21 in Monza. ADVENT NCT06891781 compares adaptive and conventional DBS in Parkinson’s disease; enrollment is under way, with104participants/up to18sites intended rather than already enrolled. U.S. use remains investigational under an FDA InvestigationalDeviceExemption, with no FDA commercial clearance or approval. Other named conditions on the site remain investigational/emerging applications. Primary financing sources establish EUR1.7M first venture financing in2016, EUR8.4M SeriesA in2019, a separate EICAccelerator grant agreement with exact EUR2,499,999 EU contribution in2023, EUR2M additional EIC equity finance announcedJanuary22,2024 and EUR13.6M SeriesB announcedFebruary13,2025. An additional MichaelJFoxFoundation grant is corroborated but its amount and exact award day are unpublished. Grant commitments, project budgets, earlier selection dates and programme maxima are distinguished from actual disbursements or new equity. Current OrigineSGR is the exact same legal manager historically called InnogestSGR; historic Innogest participation is retained under that canonical manager, rather than creating a namesake investor. Other named buyers require full verified institutional profiles before linkage, and an undisclosed familyoffice is not invented as a company.

Yang Cheng is the member/control person named in iSeed Ventures LLC’s 6 March2026 Form ADV ScheduleA, CRD297342/802-114472. It reports an October2014 appointment and CRD6955614; the exact joining day, operational title and authentic portrait are unpublished in the sources reviewed. The manager’s own LinkedIn page names Bryan Cheng, but a reliable primary alias bridge to this legal name has not been established and no general-partner title is inferred. This scoped legal identity is distinct from the existing Delos Capital associate Yang Cheng; no unrelated academic career or portrait is copied.

Adam How Lin is the managing member and chief compliance officer of iSeed Ventures LLC, confirmed by the adviser’s 6 March2026 Form ADV, CRD297342/802-114472. The filing reports this appointment from October2014 without an exact day. Primary FundIV’s 17 May2024 FormD names Adam Lin as executive officer and managing member of its GP at the same San Francisco office. mySugr’s own 2015 financing release names Adam Lin for iSeed’s early-stage digital-health investment approach and US/China core markets. This investor is distinct from Gunderson Dettmer’s Of Counsel Adam Lin and the Largan executive of that name; no lawyer/industrial executive portrait, degree or biography is borrowed.

Leonie France van Hofwegen is recorded by Companies House as a current designated member of Force Over Mass Capital LLP, appointed February21,2024. This is a statutory LLP capacity, not evidence of an investment-partner or operating job title. The current firm site publishes no individual career biography or caption-bound portrait for her. Her professional history, exact investing responsibilities and any personal investment activity remain unverified.

Equirus Wealth is an Indian wealth-management and investment business and the disclosed legal investment manager of Equirus InnovateX Fund. Its wealth services include portfolio construction, mutual-fund and alternative-investment distribution, equity and debt investing, estate planning and family-office solutions. Through InnovateX it backs early-stage technology businesses in deep tech, software and SaaS, artificial intelligence and fintech, combining venture capital with founder mentoring, commercial networks and access to the wider Equirus group’s fundraising and exit expertise. The investment manager is Equirus Wealth Private Limited, CIN U74995MH2018PTC308551; InnovateX is a separate fund scheme within Equirus Alternative Fund Trust, not the name of a separate management company.

Abhijit Bhave was identified as Managing Director and CEO of Equirus Wealth in its own October30,2024 Chariots of Fire event announcement. Current tenure is not established by that dated publication; the current directory separately identifies Ankur Punj as Managing Director.

Ajay Sampath is published as Managing Partner for Equirus Family Office in Equirus Wealth’s own directory. He advises affluent families on wealth preservation, investment growth, asset allocation and intergenerational planning. His previous wealth-management experience includes Standard Chartered, Morgan Stanley and Kotak; the family-office function is distinct from a fund investment role.

Ajit Deshmukh is named in InnovateX’s investment-manager disclosure as a member of its key investment team. Equirus separately describes him as a group Managing Director with investment-banking experience. This establishes the fund-team affiliation without assuming he is Managing Director of the Equirus Wealth legal entity.

Ankur Punj is Managing Director of Equirus Wealth. His career spans banking, wealth management and insurance, including building Equirus’s wealth business and earlier positions with Citibank, Aviva and MetLife.

Dinesh Nair is published as Director in Equirus Wealth’s wealth-distribution directory. His finance and banking career includes Geojit Private Wealth, Karvy, ICICI Securities, Axis Bank, Kotak and other financial-services firms. He works on business growth, client relationships and wealth distribution.

Jinesha Mehta is named as compliance officer in the current issuer disclosure for Equirus InnovateX Fund. The reviewed source does not publish a further biography or appointment date.

Krishna Jha is the published fund manager of Equirus InnovateX Fund. He founded mobile-internet company ITFinity, which was acquired by OnMobile, and has been an angel investor since 2011. His work combines entrepreneurship, long-term investing and support for early-stage technology founders.

Nitesh Arora is published as Managing Partner for Equirus Family Office in Equirus Wealth’s own directory. His career includes wealth-management work at Kotak and Barclays and entrepreneurship. The affiliation is explicitly a family-office function; legal employment by the InnovateX investment manager is not inferred.

Sadhika Agarwal is Principal at Equirus InnovateX Fund. She previously founded a consumer brand and worked in investment banking, fundraising and technology-sector mergers and acquisitions. She helps founders with financing, business development and operational execution.

Sunder Nookala is published as an InnovateX adviser in the current issuer directory and as Partner in the February2026 fund-close announcement. A Chartered Accountant and IIM Ahmedabad MBA, he has founded SaaS businesses and supports early-stage startups with mentorship, strategic advice and investment experience. The role-source dates are preserved because the publications use different titles.

VP Gopan is the issuer’s named InnovateX Venture Partner, also listed as Gopan V P in its legal disclosure. His published biography describes technology-product marketing, strategy and commercial experience at Wipro and Intel across international markets. Initials are preserved; no expanded given name or current outside employment is inferred.

Turbine Capital is a Stockholm venture capital firm backing early-stage research-based deep tech companies, primarily in Sweden and the Nordic region. It combines patient financing over a 15-year fund horizon with university incubator networks and corporate partnerships to help technologies move from research and prototypes into industrial deployment and international markets. Its investments include semiconductor interconnects, optical communications for AI datacenters, silicon-carbide manufacturing, energy storage, industrial efficiency and AI-designed proteins for water treatment. The firm was initiated by the Sting incubator and connects founders with industrial customers and partners including Saab, Volvo Cars, Stena Sessan and Scania.

Venture investor and corporate partnership builder previously an investment director at Investor Growth Capital and a Combient co-founder. His background includes industrial co-investments and technology company exits.

Early-stage technology operator and investor with experience in sustainable materials, SaaS growth and data. Co-founded Greewave and has worked on startup equity financing and non-dilutive funding.

Venture investor and former deep tech chief executive with previous investment experience at Almi Invest GreenTech and operational experience in B2B technology businesses.

Startup ecosystem builder who developed the Sting incubator and initiated Propel Capital and Luminar Ventures. He has supported research-based technology companies across multiple sectors.

Headlight is a technology-enabled mental-health care company providing in-person and virtual talk therapy, psychiatry and medication management. Its interventional-psychiatry services include transcranial magnetic stimulation and clinic-administered esketamine treatment for eligible patients. Founded by psychiatrists Manish Sheth and Shashita Inamdar, the business previously operated as Sokya Health before adopting the Headlight brand in 2024. Care coordinators help patients find clinicians according to their needs, preferences and insurance coverage. The company develops onboarding, medical-history integration, provider-matching and administrative workflows to make care easier to access and allow clinicians to spend more time treating patients. Headlight’s published services cover concerns including depression, anxiety, trauma, ADHD and relationship difficulties, with individual and couples therapy among its offerings. Its current care directory allows patients to filter clinicians by location, insurance, care type, specialty and availability. The company’s privacy policy identifies the operator as Headlight Health, Inc.; affiliated clinical practices are not assumed to be separate financing recipients. Current published service locations span Alaska, California, Colorado, Oregon, Texas and Washington. PACE Healthcare Capital lists Headlight in its own institutional portfolio, while the company separately announced USD18 million in new venture funding from Matrix and EPIC Ventures in February 2024.

Healthcare executive who previously led business operations at PillPack and Amazon Pharmacy before joining Headlight.

Prenosis is a Chicago healthcare technology company developing biology-based AI tools for precision medicine in acute care. Its Immunix platform combines biological specimens, biomarkers and longitudinal hospital-record data to develop and deploy diagnostic and treatment-selection tools. Its Sepsis ImmunoScore software uses up to 22 electronic-health-record inputs to assess a suspected-sepsis patient’s risk of having or developing sepsis within 24 hours. The FDA granted Class II De Novo marketing authorization on April 2, 2024; the software supports clinical and laboratory assessment and must not be the sole basis of a sepsis decision. Prenosis integrates the tool into hospital records and has a Roche Diagnostics commercial-distribution collaboration. Other precision-therapy applications and corticosteroid-response companion-diagnostic studies remain development and research programs, rather than separately authorized treatments.

Angela Thomas is Prenosis’ Chief Financial Officer. Her previous work includes biotechnology-company finance and public accounting, including Sony Biotechnology and PwC. She studied public accounting at Illinois Wesleyan University and business administration at the University of Florida.

Avinash Sastry leads engineering at Prenosis. His experience spans software, firmware, quality assurance, architecture and regulated medical-device software, including AI healthcare systems.

Bobby Reddy co-founded Prenosis and leads its strategy, clinical partnerships and product development. He trained in electrical engineering at Illinois and UC Irvine.

Brian Bray develops clinical information systems, clinical data warehouses and hospital integration tools. Before his Prenosis appointment he worked as a clinical-data integration architect at Verily.

Carlos Lopez-Espina has helped develop Prenosis’ biological and clinical data platform. His earlier work spans medical devices, diagnostics, regulatory clearances and commercial launches; he studied aeronautical and mechanical engineering.

David Sihai Zhao develops statistical methods for large biological datasets, genomics and multi-omics analyses. He trained in biostatistics at Harvard.

Edward Ogunro previously led scientific research and development at Hospira and held hospital-products and diagnostics leadership positions at Abbott.

Gary Kurtzman is a physician, biotechnology entrepreneur and healthcare investor whose previous work includes Safeguard Scientifics, BioAdvance and Gilead Sciences.

Jim Sianis has commercial healthcare-data and pharmaceutical experience, including PINC AI’s Healthcare Database and Merck. He trained in pharmacy at Temple and business at Penn State.

Jim Zhao is named in Prenosis’ shared biography directory with the external caption Senior R&D Director, Foxconn Interconnect Technologies. A company employment, directorship or advisory appointment at Prenosis is not established by that caption.

Meghann Howland leads clinical work at Prenosis after clinical research leadership at PanCan, Iqvia Biotech and Worldwide Clinical Trials. Her experience includes emergency and critical care nursing.

Nam Nguyen is an informatics adviser published by Prenosis. His biography describes healthcare data management, clinical decision support and analytics-platform experience at IMS Health, Practice Fusion, Allscripts and Veradigm. His identity is kept separate from the existing DeepWork Capital investor with the same name.

Nathan Shapiro is an emergency-medicine clinician and researcher. Prenosis’ biography describes his Harvard and Beth Israel research work, sepsis studies and experience evaluating clinical biomarkers.

Philip Verhoef is an adult and pediatric critical-care physician and immunology researcher whose work includes sepsis biology, laboratory models and clinical datasets.

Pratik Sinha is a physician-scientist studying precision treatment in sepsis and acute respiratory distress syndrome. He trained in the UK and Australia and undertook doctoral work at Imperial College London.

Rashid Bashir co-founded Prenosis and advises the company. An Illinois bioengineering professor and engineering dean, he researches biological engineering and has earlier semiconductor-commercialization experience.

Robin Carver has clinical and commercial experience in acute-care technology, including previous vice-president work at Premier and nursing education at East Carolina and UNC.

Ruoqing Zhu researches personalized medicine, survival analysis, reinforcement learning and statistical machine learning. He trained at UNC and Yale before joining Illinois.

Sean Murphy previously led corporate M&A and business development at Abbott, co-founded Malin Life Sciences and worked at Evercore.

Suzanne Lebold advises biopharma businesses on strategy, licensing and acquisitions after business-development leadership at Abbott and AbbVie.

William Harty specializes in healthcare interoperability and enterprise medical-software integration. His Prenosis biography describes infection-surveillance software and computer-science and business training at Vermont.

Unlikely Collaborators is a nonprofit storytelling, experiential and philanthropic organization that helps people examine the mental models, beliefs and personal narratives shaping their perception and relationships. It creates films, podcasts, conversations, immersive gatherings and practical reflection tools around founder Elizabeth R. Koch’s Perception Box framework, and supports community organizations through grants and creative partnerships. Its published Unlikely Investments strategy also backs leaders and early-stage companies, particularly at seed and Series A in mental health and wellness, neurotechnology and psychedelic medicine. Backpack Healthcare independently names it as an equity-round participant. Current website terms and privacy identify the operator as Unlikely Collaborators, Inc.; the brand’s investment activity does not establish a separately raised venture fund or identify every historical legal subscriber.

Elizabeth R. Koch is a writer and social entrepreneur who founded Unlikely Collaborators and developed its Perception Box framework for exploring beliefs, identity and experience. Her own biography separately identifies her founding work with Tiny Blue Dot Foundation and The Elizabeth R. Koch Foundation; those organizations are not merged with Unlikely Collaborators.

Sarah Haberman leads community and impact at Unlikely Collaborators, overseeing grant-making strategy and operations and partnerships with grantees, researchers and practitioners. Previously CEO of The Moth from 2013 to 2026 and a development leader at New York cultural and educational institutions.

Genius Guild is a Chicago venture capital firm and business-creation platform founded by Kathryn Finney. It backs scalable early-stage businesses led by underestimated founders, with a particular focus on Black founders and companies improving the health and economic wellbeing of diverse communities. Its investing framework spans the social determinants of health: access to care, community connection, economic opportunity, education and the built environment. Its published specialties include pre-seed and seed investing, and it has also participated in later startup rounds. The platform originally described three complementary activities: direct venture investing through the Greenhouse Fund, incubation through Genius Guild Labs and media and thought leadership through Genius Guild Studio. Its verified investments include pediatric mental-healthcare company Backpack Healthcare and digital-health platform Health in Her HUE.

Brian Laung Aoaeh co-founded REFASHIOND Ventures and the Worldwide Supply Chain Federation. His Genius Guild residency was announced in November2021. His later career investment count and REFASHIOND rolling-fund capital are not attributed to Genius Guild.

Kathryn Finney founded Genius Guild and leads its venture investing. She previously founded digitalundivided and The Budget Fashionista, is a Yale-trained public-health professional and wrote Build the Damn Thing. Her own biography describes investments across her career; this is not treated as the complete Genius Guild portfolio.

Saidah Nash Carter works on digital innovation, inclusive business and impact. Her own biography describes Reuters NewMedia work and co-founding Bright Insights Global. Genius Guild publishes her affiliation, but does not disclose a current title.

Stacey Ferguson is a marketing and communications executive, community builder and startup founder. Her May2022 guest biography identifies her Genius Guild marketing role and earlier JusticeFergie and Blogalicious work; this is retained as historical affiliation.

Tessa Flippin founded Capitalize VC after venture investing at TechNexus and founding fintech payments platform La Plataforma. Genius Guild announced her one-year venture-capital residency in November2021; no present residency status is inferred.

Entrepreneur and investor who co-founded Collab Capital and Goodie Nation. His current personal site places his Collab co-founder and Managing Partner work in the Previously section, separately from his current investment and community roles. No exact departure date is published.

AI specialist and technology entrepreneur published as Collab Capital’s inaugural AI Executive-in-Residence in June2025. The firm describes her as a former Amazon AI leader supporting portfolio companies with on-demand AI expertise; exact appointment dates and continued tenure are undisclosed.

Public-relations consultant named as an external media contact for Collab Capital’s June2025 Fund II close announcement. The dated source establishes that engagement; an ongoing employee role or current assignment is not confirmed.

Collab Capital is an Atlanta-based venture capital firm backing seed and Series A technology companies that expand healthcare access, improve economic mobility and strengthen community infrastructure. Its founders bring experience building and selling businesses and support portfolio companies with operating advice, commercial relationships and further financing. Its healthcare investments include youth and family mental-health services, telehealth, maternal care and clinical-care coordination; its AI investments span application development, lending and nonprofit content creation. The firm emphasizes entrepreneurs with direct experience of the problems they are solving and has historically backed Black and other underrepresented founders. Fund II targets approximately30 companies, typically investing USD1million–2million with capital reserved for follow-on rounds.

Principal at Collab Capital, working on sourcing, due diligence and portfolio support. Previously invested at Vestigo Ventures and worked in corporate finance at Twitter and financial-institutions banking at JPMorgan. Graduated from Spelman College in economics and helped found BLCK VC’s Boston chapter.

Co-founder and Managing Partner of Collab Capital. Co-founded Partpic, developing computer-vision tools for identifying industrial parts, and sold it to Amazon in2016. Previously led Google for Startups in the United States, supporting underserved founders; graduated from Howard University.

Senior Investment Associate at Collab Capital, conducting market research, due diligence and portfolio support. Her background includes startup building at ACT House, entrepreneurship programming at Ed Farm and co-founding4WRDVentureCapital. Graduated from Florida A&M University and teaches entrepreneurship at Morehouse College.

GT Healthcare Capital Partners is an Asia-based private investment partnership focused on healthcare technology and cross-border company growth, with primary-published offices in HongKong and Shanghai. Its mandate supports businesses internationally and their expansion in Asia and GreaterChina. The public portfolio includes AI drug discovery, medical robotics, advanced genomics, diagnostic imaging and neuroscience technology, including Exscientia, Apeiron, Moon Surgical, Oxford Nanopore, Ultromics, Autobahn Therapeutics and OxfordVR. Its current retrieved directory publishes seven professionals, combining investment, clinical and biotechnology experience. Six separately named legal GT investment vehicles are supported by SEC agreements and issuer-regulated holdings disclosures; those documents do not establish final LP sizes or paid capital. The exact corporate manager registration suffix remains unverified, and GTM Capital/MPM-associated vehicles are not assumed to be the same manager. Portfolio therapeutic and product statements are company claims, not proof of medical effectiveness. It is distinct from US GT Capital Partners commercial lending and unrelated GP Healthcare Capital firms.

Alan Au is founder and managing partner of GT Healthcare Capital Partners, an Asia-based cross-border healthcare investment partnership. His published career includes healthcare investment banking at Deutsche Bank in2011–2012, JAFCO Asia in2008–2010, Morningside in2000–2005 and earlier KPMG financial-advisory work. The manager describes prior Simcere advisory work and Nepstar board service in2013–2016; these are historical affiliations. He studied psychology at the Chinese University of Hong Kong and management at Columbia Business School, and the manager reports US CPA and CFA credentials. Boundless Bio’s SEC-filed investor agreement identifies him as general partner signing for two separately named GT Nextgen funds. The authentic portrait is supplied by Moon Surgical’s current name-bound board-observer card. He is distinct from the HKMA banking-conduct executive of the same name.

Fred Aswad is a venture partner named by GT Healthcare Capital Partners. His primary manager biography describes biotechnology research and drug-discovery work at Bayer, including immuno-oncology programmes, followed by a senior biology position at IDEAYA Biosciences focused on small-molecule therapies and synthetic lethality. It identifies an immunology PhD from the University of Southern California. Apeiron Therapeutics’ current team page identifies him as chief scientific officer and supplies a genuine name-bound headshot. That page contains an unrelated sentence referring to Jim and a Duke degree; the inconsistent sentence is excluded. His outside scientific career does not establish personal investment allocations.

Jason Yeung is a partner named in GT Healthcare Capital Partners’ current public team directory. His primary biography describes more than twenty-five years of wealth-management and investment-banking experience, including executive positions at Credit Suisse, Merrill Lynch, JPMorgan and Goldman Sachs. It describes advising wealthy clients on equities, fixed income, derivatives, private equity and other investments, and building access to external asset managers. The reported assets managed in his previous career are not evidence of a GT fund raise. No exact appointment date, separately verified educational credentials or authentic portrait was established. The own-site name graphic is deliberately excluded as a human photograph.

Lo Yuk Lam is chairman of GT Healthcare Capital Partners and a biotechnology industry leader with experience in company governance, research and public service. The manager’s public directory names him chairman, and a2026 HKEX-filed annual report corroborates a chairmanship beginning inJuly2019 without establishing an exact day. Hong Kong Biotechnology Organization’s current primary biography identifies him as its honorary founding chairman and connects the same person to GT; its name-bound original portrait is used here. His career includes biotechnology industry development and university advisory work. Older GT biographies list some board and government titles that have changed, so those are retained as published career history rather than asserted current appointments.

Marcus Hui is vice president at GT Healthcare Capital Partners. His current primary biography says he joined in2021, with the exact month and day undisclosed. It describes earlier work helping startups at Hong Kong Science and Technology Parks, healthcare investing at a Beijing-based financial institution, and strategy and business development in medical technology and healthcare services. He studied biochemistry at Imperial College London and pharmacology at the University of Oxford. The2026 MedTech World Hong Kong programme and Startup World Cup’s own judges page independently identify his GT title; the latter supplies a genuine name-bound original publisher portrait rendition. His event affiliation does not imply any personal check.

Mingxi Li is a partner at GT Healthcare Capital Partners focused on life-science technology and cross-border commercialization. The manager describes earlier Jiuding healthcare investing and Simcere work, including a senior-director position in2013–2017. He studied biological science and biotechnology at Tsinghua University and earned a biochemistry PhD at the University of Illinois Urbana-Champaign. Apeiron Therapeutics’ current primary team biography identifies the same scientist as its CEO and a GT partner, providing a genuine name-bound portrait. His former Simcere portfolio responsibility is career history, not a GT fund closing or personal cash investment. He is distinct from an unrelated New York internal-medicine physician with the same name.

Ping Wen is a venture partner at GT Healthcare Capital Partners with clinical and medical-device experience. His primary biography identifies an eight-year clinical-medicine MD programme completed in2010 at Peking Union Medical College and the Chinese Academy of Medical Sciences. It describes six years of neurosurgical work at Zhujiang Hospital and a2014–2015 visiting-scholar period at Siena University Hospital, followed by medical-device research and commercialization from2016. The biography’s patent and product-development counts are attributed to the publisher and do not establish regulatory approval or clinical efficacy. No genuine portrait was authenticated; the own-site name graphic is excluded.

Publicly named Board Director at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Publicly named Board Chair at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Publicly named Venture Manager at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Marco has built consolidated managerial and financial experience in the Life Sciences sector, serving as Country CFO and Oncology Region Europe CFO at Novartis. Over his career he has developed solid experience in supporting entrepreneurial and business-development initiatives, with a proven track record in financial management and in growing organisations across the healthcare and pharmaceutical sector.

Lorenzo has built significant experience in venture capital and alternative investments as Co-Founder and Managing Director of Alchimia Investments, contributing to the establishment and management of investment vehicles and to capital-raising activities. He has served as Managing Director and board member of portfolio companies and, as a founding-team member, took part in the launch of major projects such as Arsenale Group and Orient Express La Dolce Vita. He is also a lecturer and Venture Capital expert at Luiss University.

Publicly named Senior Advisor, Board Director at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Publicly named Senior Advisor at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Publicly named Operating Partner at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

He has built over 5 years of experience in mid-market M&A transactions at Deloitte Financial Advisory, where he actively contributed to more than 10 deals, both sell-side and buy-side, advising entrepreneurs, private equity funds and industrial operators. Over the course of his career he has developed expertise across the ICT and cybersecurity, software and artificial intelligence, telecommunications, agri-industrial and agri-tech, and energy services sectors. He holds a Bachelor's degree from ESCP Business School and a Master of Science in Corporate Finance & Banking from EDHEC Business School.

He joined Origine in May 2026 as Investment Manager, having built around nine years of experience in the Italian mid-market private equity sector. Following roles at Armònia SGR and Entangled Capital SGR, he has taken part in numerous majority investment transactions across different industrial sectors, following all their key phases, from analysing and structuring the investment to managing and enhancing portfolio companies. He has also supported the management of portfolio companies in implementing strategic and operational value-creation initiatives.

Tommaso brings over 23 years of experience in the financial sector, more than 18 of them in private equity as a principal investor in Italian and European mid-market funds. Over his career he has managed every phase of the investment process, from origination and deal structuring through to portfolio management and exit. He has held positions of growing responsibility at leading private equity firms, including Senior Director at Green Arrow Capital, Principal at Ergon Capital, Director at Alto Partners and Junior Partner at Armònia SGR, developing significant experience in growth, sector consolidation and value-creation transactions. Tommaso began his career in corporate finance at Deutsche Bank and Lazard, where he gained experience across numerous M&A transactions.

A professional with over 25 years of experience in the financial sector, more than 15 of them in Private Equity as a principal investor in investment funds and 10 years in investment banking at Deutsche Bank. Over his career he has held prominent roles in the Italian private equity market, including Investment Director at Clessidra SGR and Partner at Armònia SGR.

Daniel has built his career across data analysis, data infrastructure, and technical systems development, with experience spanning financial, operational, and client-facing environments. He has worked as a project and data lead at Deloitte and boutique firms in the FMCG sector, and more recently has led data pipeline strategy, product architecture and implementation, and client delivery within SaaS environments. He holds a Master’s degree in Physics from the University of Bristol.

Publicly named Executive Assistant at Origine SGR S.p.A., the Italian private-markets manager previously called Innogest SGR. This affiliation is confirmed by the manager’s current public directory as reviewed October 8, 2026.

Teresa Sanseverino is named in the fund-management function of Origine SGR, previously Innogest SGR, by its current public directory. The source does not disclose additional current responsibilities.

Marialiliana has built significant experience across administrative, financial and operational functions within the management of alternative investment funds, at leading asset managers active in private equity and venture capital. Over her career she has held senior roles including Chief Financial Officer, Chief Operating Officer and Head of Administration at firms such as Ambienta SGR, Hyle Capital Partners SGR and I2 Capital Partners SGR, also developing expertise in ESG and risk management. As Chief Financial Officer of the SGR, she oversees its administrative, financial and operational activities, contributing to process efficiency and regulatory compliance.

Investment banker, principal investor and entrepreneur with consolidated experience across the public and private sectors, with particular specialisation in telecommunications and digital transformation, energy and the agri-food supply chain. Over his career he has held senior roles, including Senior Managing Director at Macquarie, Senior Partner at Vitale & Co and Head of the Telecommunications Department at the Italian Ministry of Economic Development (MISE).

Origine SGR S.p.A. is an Italian private-markets investment manager based in Milan, operating private-equity and venture-capital strategies. Its current venture portfolio includes neuroscience and medical-device businesses Newronika, Anaconda Biomed and Empatica, alongside other MedTech, life-sciences and digital companies. Its current VC funds are in the divestment and value-creation phase. Origine Growth PE Fund is a separate operational PIR-compliant strategy focused on Italian SMEs, industrial technology and business transformation, agri-food technology, energy transition, aerospace, defence and safety. The manager is the legal continuation of Innogest SGR, not a separate namesake investor: primary GLEIF record LEI984500BA36B52C7C7D83 retains Italian registration/VAT09050910018 and lists Innogest SGR and Innogest Vertical Funds SGR as previous legal names, with the change to Origine SGR effective October15,2025. Legal incorporation is recorded January21,2005; historical Innogest announcements describe the investment platform as established in2006. Historic Innogest portfolio investments are therefore attributed to this same manager with their original brand and timing qualified. Current headquarters are Via Napo Torriani31,20124 Milan. Historical Turin/SanFrancisco offices are not asserted current. The profile includes all seventeen unique people and twenty-one affiliations publicly named in the current management, private-equity, venture-capital, operating-adviser and board directories. Nine genuine published portraits are available; eight other named members have no portrait published on that directory. Former Innogest partners are not asserted as current employees. The venture team currently lists Lorenzo Castelli, Marco Venturelli and Carlotta Riccio. Historical fund evidence supports approximately EUR85M final commitments for Innogest CapitalII announced September21,2015 and EUR40.9M for IPGest including its EUR20M public component. CapitalI and the current GrowthPE fund are retained without invented sizes or exact closing dates. Neither manager AUM, an earlier included CapitalII close, a new fund fundraising target nor the GrowthPE strategy’s EUR20–45M portfolio ticket range is recorded as additional raised capital. Current own portfolio places Empatica investment in Q4,2016 without naming exact cash, stage or day; this does not allocate an institution to a protected personal-investor signal. Portfolio support is not proof of medical efficacy or product regulatory approval.

Ashish Narendra Patel, published professionally as Dr Ash Patel, was the Optum Ventures principal appointed to OxfordVR’s board in the February2020issuer financing announcement. Companies House records his full legal name and historical director term. Mercia’s own earlier professional interviews and authored life-sciences research corroborate the physician-investor career before Optum. He is distinct from the existing Kenya-based Antler fractional CTO Ashish Patel; no homonym merger or personal investment is inferred.

Deepak Gopalakrishna led OxfordVR during its later independent period, documented by his2022IVRHA speaker biography and its issuer announcements. His published biography reports an MBA and doctorate in genetics and molecular biology, earlier academic work on congenital disorders, healthcare entrepreneurship and work scaling BCG Digital Ventures. He also founded Rey, a distinct2021USmental-health company that announced plans to absorb OxfordVR. Exact receiving-entity allocations are not assumed from that business relationship.

Mavi Sánchez-Vives, formally María Victoria Sánchez-Vives, is a physician and neuroscientist who leads systems neuroscience at IDIBAPS as an ICREA research professor. Her own ICREA biography describes doctoral neuroscience training, postdoctoral work at Rockefeller and Yale, and co-direction of the Event Lab. Jason Freeman’s Oxford university biography explicitly names her as an OxfordVR co-founder. This scientific founding affiliation is historical, without an inferred current commercial position or personal investment.

Bernhard Spanlang is a computer-graphics and virtual-reality researcher named as an OxfordVR co-founder in Jason Freeman’s university biography. UCL documents his engineering doctorate in cloth modelling and visualization, involving physically based simulation and virtual clothing. His published professional profile describes later immersive-technology work at Kiin. The OxfordVR founding affiliation is historical and does not imply a present executive role or financial check.

Dean Noakes was OxfordVR’s IT manager according to its historical public company directory. His own professional profile and a colleague recommendation corroborate that OxfordVR work, alongside a later Qube Research & Technologies affiliation. This record retains the historical technical-support role; no current OxfordVR employment, precise dates or unverified academic qualifications are asserted.

Mel Slater is a virtual-environments scientist and OxfordVR scientific co-founder, explicitly named in Jason Freeman’s Oxford university biography. His published academic CV describes research leadership at Queen Mary, UCL and Barcelona and work on presence and embodiment in virtual environments. He is distinct from an unrelated US Army namesake. His OxfordVR statutory directorship ended in2017; a historical founding affiliation is not a current company management position.

Polly Haselton is a cognitive behavioral therapist named as OxfordVR’s psychologist in its historical directory and an author of its2018height-phobia clinical study. Her own practice biography describes Cardiff psychology training and postgraduate psychological-therapy study at Exeter and Oxford, together with NHS and research work. Her later published career includes other digital-health organizations. The historical OxfordVR role does not establish current employment.

Aitor Rovira is an Oxford virtual-reality technology researcher whose work combines computer science, immersive interaction and psychology. His university biography describes a UCL computer-science doctorate, postdoctoral research at Japan’s Nara Institute of Science and Technology, and joining Oxford in2017. He supervises software and hardware for therapeutic research and trials. OxfordVR’s older directory names him head of VR strategy; that historical commercial affiliation is distinct from his university role.

Andrew Forster was OxfordVR’s lead artist according to its published historical directory. His own professional profile is corroborated by Sam Gage’s recommendation naming the OxfordVR lead environment artist role. This is the immersive-therapy visual artist, not another similarly named investor or engineer. The source does not verify a current OxfordVR role, degree or exact employment dates.

Thiago Craveiro, also professionally published as Thiago Escudeiro Craveiro, was a programmer on OxfordVR’s historical team. The company directory lists that role, and his own profile carries colleagues’ recommendations identifying him as the first programmer in Sam Gage’s OxfordVR team. His published profile also describes software and iOS development. Exact company dates and a current OxfordVR position are not inferred.

Sam Gage led virtual-reality development at OxfordVR according to the company’s published historical directory. His professional profile and colleagues’ published recommendations corroborate leadership of its Unity-based therapeutic VR development team. The affiliation is historical; current OxfordVR employment, exact dates and educational qualifications are not established by the available primary company biography.

Flerie is a publicly listed, evergreen life-sciences investment company that builds biotechnology, pharmaceutical and related technology businesses using its own balance sheet. It invests across product development and commercial growth, combining financing with active board work, development planning, operational support, licensing and partnerships. Its portfolio spans immuno-oncology, metabolic disease, biologics, gene therapy, manufacturing, diagnostics and related services. Flerie supports portfolio CEOs through its Flerie and Peers network and syndicates with other investors internationally. It aims to remain invested while it can contribute to company development, rather than applying a conventional fixed-life venture-fund timetable. The platform began as Flerie Invest in2011; the current listed parent, Flerie AB (publ), emerged from a2024 reverse merger and trades on Nasdaq Stockholm. Its corporate share issues, net asset value and financing facilities are distinct from closed-end fund commitments.

Anders is a board member with medical and pharmaceutical-development experience, including prior global medicines-development leadership at AstraZeneca.

A physical chemist and biotech executive, Arvid joined Flerie as venture partner in2026. Flerie separately identifies him as Empros Pharma’s CEO.

Carl-Johan has been a senior adviser since April2021. His published background includes pharmacology and a long career at Recipharm.

Cecilia is a board member and audit-committee chair. Her published experience includes finance, corporate relations and life-sciences leadership.

Cecilia leads finance and serves as deputy CEO. The current management biography distinguishes appointments at the listed company in2024 from earlier Flerie Invest duties.

Fredrik joined as senior adviser in2026. His background includes drug-development operations, research, manufacturing and biotechnology company-building.

Holger joined the board in2026. Flerie describes his molecular-biology background and external biopharmaceutical business-development and alliance-management experience.

Jenni is a board member with chemistry and life-sciences policy experience. Her published biography identifies prior government and innovation-agency duties.

José is a US-based venture partner. His published biography describes life-sciences transactions, executive leadership and legal experience.

Lars is published as a nomination-committee member appointed by Cajelo Invest Ltd. This shareholder-governance role is distinct from operating employment.

Manuela joined in June2025 as assistant to CEO Ted Fjällman, following support roles in insurance and other industries.

Mark is a partner and management-team member with business-development, M&A and supply-chain experience, including prior Recipharm leadership.

Mattias is published as a nomination-committee member representing the Fourth Swedish National Pension Fund. This is a shareholder-governance affiliation, not Flerie employment.

Michaela is published as head of investor relations and described as a senior adviser. She has finance and fundraising experience and separately works as an independent consultant.

Paula joined in January2024. Her background includes finance, private equity, analysis, business development and founding a Swedish startup.

Ted is CEO and a management-team member. His background includes biotechnology research, clinical research and strategy consulting, with earlier portfolio-company leadership.

Thomas founded the Flerie investment platform in2011 and is its executive chairman. He previously co-founded Recipharm and participates in Flerie’s board committees.

Christophe Faucherand is a healthcare product leader listed as OxfordVR’s chief product officer in its historical company directory. His own professional profile describes more than15years building products and a later electronRx affiliation. This record preserves the source-published OxfordVR product role without asserting current employment or an unverified appointment date; additional degree and career details are not supplied by the company directory.

Katie Bedborough was OxfordVR’s finance and operations leader during its independent fundraising period. The Oxford Trust’s January2020 interview identifies her as both COO and CFO, while the February2020 issuer financing announcement credits her work on the completed Series A. The old directory lists CFO. Her historical statutory director term is documented by Companies House; no current standalone OxfordVR executive position or undisclosed education is assumed.

Jason Freeman is a virtual-reality treatment designer in Oxford’s Cognitive Approaches to Psychosis group. His own university biography describes work on Phoenix, gameChange, height and needle phobia treatments, and the digital Feeling Safer intervention. It explicitly names him as an OxfordVR co-founder alongside Daniel Freeman, Mel Slater, Bernhard Spanlang and Mavi Sánchez-Vives. OxfordVR’s older public directory lists him as COO. The historical company role and statutory director term are separate from his current academic work.

Barnaby Perks is an engineer and digital-health entrepreneur who led OxfordVR before its later business combinations. Its 2018 and February2020 announcements name him as CEO; the old company website is therefore treated as a historical roster. His published Digital Youth biography describes biomedical engineering research at Dundee, assistive-technology development and founding leadership of Ieso. He became St John’s Innovation Centre CEO in April2024. The Companies House record supplies the separate historical OxfordVR statutory director term.